atai Life Sciences Announces Successful Outcome of Phase 2a

RL-007 was well tolerated and demonstrated a clinically meaningful pro-cognitive profile Changes in quantitative electroencephalogram (qEEG) were consistent with the results of a previous Phase 1 trial

Related Keywords

New York , United States , Chad , Berlin , Germany , London , City Of , United Kingdom , Brandtj Hopkins , Camilla Dormer , Clin Psychopharmacol , Richard Se Keefe , Matthew Pando , Life Sciences Nasdaq , Founder Of Recognify Life Sciences , Recognify Life Sciences , Exchange Commission , Assessment Inc , Treatment Research To Improve Cognition In Schizophrenia , Life Sciences , Duke University , Cognitive Impairment Associated , Brief Assessment , Symbol Coding Test , Symbol Coding , Hopkins Verbal Learning Task , Treatment Research , Improve Cognition , Consensus Cognitive Battery , Florian Brand , Recognify Life , Opinion Leader Event , Symbol Substitution Test , Sensitivity Over Specificity , Accessed December , Findings From , Global Burden , Disease Study , Cognitive Enhancement , Patients With Schizophrenia , Bipolar Disorder , Private Securities Litigation Reform Act , Securities Act , Jatai , Life , Ciences , Nnounces , Uccessful , Outcome , Hase , Biomarker , Trial , Cognitive , Impairment , Ssociated , Schizophrenia ,